April 26, 2019 Healthcare, Top Market News 0 Comments Cantor Fitzgerald Remains a Buy on Aclaris Therapeutics Inc (ACRS) By Carrie Williams
[Cantor Fitzgerald Remains a Buy on Aclaris Therapeutics Inc (ACRS)] In a report released today, Louise Chen from Cantor Fitzgerald maintained a Buy rating on Aclaris Therapeutics Inc (ACRS ? Research Report), with a price target of $50. The company?s shares closed yesterday at $6.83, close to its 52-week low of $5.04.
?We expect upwards earnings revisions to levels not reflected in sell-side consensus expectations to drive shares higher. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of 50 USD.